Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02677064 · ClinicalTrials.gov registry record
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
A clinical trial of Acute Leukemia and Newly Diagnosed, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 1,365
- Enrollment target
- 3
- Study locations
NCT02677064 is a study of Acute Leukemia and Newly Diagnosed that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1,365 participants, above the 426-participant average among 37 other Acute Leukemia trials with a reported enrollment target (220% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT02677064, a study of Acute Leukemia and Newly Diagnosed, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 1,365 participants
- Enrollment target
- 3
- Study locations
Study Summary
The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explore why some patients elect not to undergo stem cell transplantation, when it is recommended by their physicians.
Conditions Studied
Interventions
- OTHER assessments
Study Locations (3)
Connecticut
- Hartford Healthcare Cancer Institute @ Hartford Hospital - Hartford
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,365 participants |
| Start Date | 2016-02 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02677064
The ClinicalTrials.gov registry entry for NCT02677064 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,365 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 426-participant average among 37 other Acute Leukemia trials with a reported enrollment target (220% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Leukemia appearing as the primary indexed condition, and to 1 intervention - of which assessments is the first listed.
NCT02677064 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02677064 about?
NCT02677064 is a clinical study titled "Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia". The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explor...
What is the current status of trial NCT02677064?
This trial is currently recruiting. The enrollment target is 1,365 participants. The study started on 2016-02. Estimated completion is 2027-02.
What conditions does trial NCT02677064 study?
This clinical trial studies the following conditions: Acute Leukemia, Newly Diagnosed, Relapsed.
What interventions are being tested in trial NCT02677064?
The interventions under investigation include: assessments (OTHER).
Who is sponsoring clinical trial NCT02677064?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02677064 being conducted?
This trial has 3 study locations across Connecticut, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
RECRUITING · NA
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
RECRUITING · Phase 1
-
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.